Harvard Health Letter

News briefs: Biologic therapy doesn't raise cancer risk in people with rheumatoid arthritis

Despite theoretical reasons to worry that biologic response modifiers may raise cancer risk, it appears they don't significantly raise the risk of malignancy. The drugs can dramatically improve inflammation in people with rheumatoid arthritis.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In